Pancreatic adverse events in patients treated with immune checkpoint inhibitors.

Background And Aim: The inhibition of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) has been a target for multiple drugs to enhance the T-cell antitumor activity. However, these immune checkpoint inhibitors (ICIs) come with a panel of immune-related adverse events (irAEs) that include mainly endocrine, skin, and gastrointestinal effects. We report seven cases of pancreatic irAEs in patients treated with ICIs at our institute.

COVID-19 mRNA Vaccine-Associated Myocarditis Presenting as STEMI in a 48-Year-Old Male.

Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations. Young adult and adolescent males < 30 years of age are the most commonly affected group, with decreased incidence with older age. This is a case of a 48-year-old male who presented with chest pain and EKG findings of STEMI shortly after receiving the second dose of the Moderna COVID-19 mRNA vaccine.

Meropenem-Resistant Pandoraea Pneumonia in a Critically Ill Patient With COVID-19.

Among patients infected with respiratory viruses, primary coinfection or secondary bacterial pneumonia is common in the severely ill. are multi-drug resistant gram-negative bacilli that have been newly classified in the past 20 years. We present the first reported case of co-infection with SARS-CoV-2 infection.